Ajanta Pharma Sustainability Profile
Ajanta Pharma Limited, headquartered in India, is a prominent player in the pharmaceutical industry, specialising in the development and manufacturing of a diverse range of formulations. Founded in 1973, the company has established a strong presence in various operational regions, including Asia, Africa, and the Middle East. Ajanta Pharma is renowned for its focus on therapeutic areas such as ophthalmology, dermatology, and pain management, offering unique products that cater to specific medical needs. With a commitment to quality and innovation, the company has achieved significant milestones, including numerous approvals from regulatory authorities worldwide. Recognised for its robust market position, Ajanta Pharma continues to expand its global footprint, driven by a dedication to enhancing patient care through effective and affordable healthcare solutions.
DitchCarbon Score
How does Ajanta Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ajanta Pharma's score of 18 is lower than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ajanta Pharma's reported carbon emissions
In 2024, Ajanta Pharma reported significant carbon emissions from its operations in India, with Scope 1 emissions totalling approximately 6,390,220 kg CO2e and Scope 2 emissions reaching about 40,007,740 kg CO2e. This reflects a commitment to transparency in their environmental impact, although no Scope 3 emissions data has been disclosed. Comparatively, in 2023, the company recorded Scope 1 emissions of about 4,368,550 kg CO2e and Scope 2 emissions of approximately 51,847,350 kg CO2e. This indicates a slight increase in Scope 1 emissions year-on-year, while Scope 2 emissions have decreased. Ajanta Pharma has not set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, indicating a potential area for future commitment. The company’s emissions data is not cascaded from any parent organisation, ensuring that the reported figures are solely reflective of Ajanta Pharma's own operations. Overall, while Ajanta Pharma has made strides in reporting its emissions, the absence of reduction targets suggests an opportunity for enhanced climate action and commitment to sustainability in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 3,660,360 | 0,000,000 | 0,000,000 |
| Scope 2 | 41,756,300 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Ajanta Pharma's Industry?
How Carbon Intensive is Ajanta Pharma's Location?
Ajanta Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ajanta Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
